相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1897
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The global probiotic micro-pellets market is projected to grow from USD 378.4 million in 2026 to USD 1,103.9 million by 2036, reflecting an 11.3% CAGR. - Lactobacillus strains hold the largest share at 37.5% in 2026, while enteric/acid-protective coatings lead the coating segment at 36.7%. - North America accounts for 38.5% of the market in 2026, with India projected as the fastest-growing country at a 10.3% CAGR through 2036. - Buyer decisions hinge on documented dose uniformity, coating performance, release behavior, and GMP compliance rather than category growth claims alone.
- The FDA has cleared CoRegen's IND application for CRG-150, a first-in-class adoptive cell therapy targeting the SRC-3 master gene regulator in Treg cells. - The Phase 1/2a trial will enroll patients with metastatic triple-negative breast cancer, HR+ HER2− breast cancer, and metastatic prostate cancer to assess safety and preliminary efficacy. - Preclinical studies demonstrated complete tumor eradication and durable protection against recurrence in mouse models without systemic autoimmunity. - CoRegen has partnered with Lonza for manufacturing and plans to expand into glioblastoma and pancreatic cancer in the future.
- The global exosome drug delivery services market is projected to grow from $4.85 billion in 2025 to $24.33 billion by 2035, driven by a 17.5% CAGR. - Cancer drug delivery dominates applications with a 32% market share, while RNA therapeutics delivery is the fastest-growing segment at 21% CAGR. - Mesenchymal stem cell-derived exosomes lead sourcing at 48% share, but plant-derived exosomes are emerging as the fastest-growing alternative at 20.5% CAGR. - Key milestones include Capricor's PDUFA date in August 2026 and the RION-Lonza collaboration advancing commercial-scale cGMP manufacturing.
- Nona Biosciences and Lonza announced a strategic collaboration to develop best-in-class single-domain antibody-based blood-brain barrier (BBB)-crossing technology for central nervous system diseases. - The partnership leverages Nona's proprietary Harbour Mice® fully human HCAb platform alongside Lonza's GS Gene Expression System® and GlycoConnect® bioconjugation technology. - Nona will receive upfront and option payments from Lonza, with both parties sharing revenues from future licensing agreements generated through the collaboration. - The collaboration aims to enable delivery of diverse therapeutic modalities into the CNS, unlocking new opportunities in drug development and technology licensing for devastating neurological disorders.
- Lonza and Antharis Therapeutics announced an exclusive, target-specific licensing agreement to develop novel dual-payload antibody-drug conjugates (ADCs) targeting gastrointestinal cancers. - Antharis will combine its proprietary antibody engineering and target biology expertise with Lonza's clinically validated, site-specific dual-payload ADC technology platform. - The collaboration will initially support Antharis' lead ADC program, which is about to enter clinical trials, with the goal of overcoming multi-drug resistance and improving overall survival rates. - Under the agreement, Antharis retains full responsibility for research, clinical development, manufacturing, and commercialization, while Lonza is eligible for upfront, milestone, and royalty payments.
- Lonza has strengthened its preclinical development offering with an enhanced DNA-to-IND programme designed to accelerate timelines and reduce development risk for biologics. - The new GS Ori-Go vector technology enables lead-clone titers higher than 11 g/L and a more than 30% increase in titers across monoclonal antibodies, bispecifics, and fusion proteins. - Monoclonal antibody programmes can now achieve IND readiness in as little as 6 months, with toxicology-grade drug substance available in approximately 2 months. - The enhanced offering integrates early de-risking, accelerated execution, and regulatory insight to help biotech companies progress high-quality biologics to the clinic with greater confidence.
- Gammaretroviral vectors are re-emerging as a powerful gene delivery tool, particularly in CAR-T therapies where they already have a proven commercial track record. - Many retroviral programs stall not in early development but during the transition to clinical and commercial manufacturing due to legacy production approaches and vector fragility. - The industry is shifting toward purpose-built manufacturing strategies including fixed-bed bioreactors, stable producer cell lines, and serum-free processes to improve scalability. - Closing the industry-wide experience gap in large-scale retroviral vector production requires closer collaboration across the CGT ecosystem and integrated development strategies.
- Sidewinder Therapeutics secured $137 million in Series B financing co-led by Frazier Life Sciences and Novartis Venture Fund to advance next-generation bispecific antibody-drug conjugates. - The company is developing bispecific ADCs that target receptor co-complexes highly expressed on solid tumors, combining an oncogenic driver receptor with an internalizing receptor for enhanced precision. - Sidewinder plans to focus on cancer indications with limited treatment options affecting large populations, including colorectal tumors, squamous cell carcinomas in lung and head and neck cancers. - The company expects to advance its lead program into clinical development in 2027, with total funding now reaching $162 million since its 2023 founding.
- Lonza has agreed to divest its Capsules & Health Ingredients business to Lone Star Funds for an enterprise value of CHF 2.3 billion ($3 billion), marking the final step in its transformation to a pure-play CDMO. - The company will receive CHF 1.7 billion ($2.2 billion) in upfront cash proceeds while retaining a 40% stake with preferential participation in future exit proceeds. - Total undiscounted value from the full CHI exit is expected to reach or exceed CHF 3 billion (~$4 billion), providing significant capital for reinvestment in CDMO operations. - Lonza plans to return CHF 500 million to shareholders through share buybacks and will focus its three complementary CDMO business platforms powered by the Lonza Engine.
- MacroGenics is developing three innovative antibody-drug conjugates (ADCs) targeting B7-H3, ADAM9, and an undisclosed antigen, with initial clinical data expected from MGC026 and MGC028 in 2026. - The company's ADC programs have demonstrated acceptable safety profiles with no interstitial lung disease observations and early evidence of anti-tumor activity by RECIST criteria. - MacroGenics maintains a strong financial position with $189.9 million in cash and securities, providing runway into late 2027 to support clinical development milestones. - Partnership programs with Gilead, Sanofi, and Incyte continue to progress, with MacroGenics eligible for up to $2.47 billion in future milestone payments across all collaborations.
